Citations

Showing 10 of 107875 citations.

Congenital myasthenic syndrome: is it time for a name change to genetic myasthenic syndrome?
Ramdas, Sithara , Dong, Yin Yao , Munot, P., Benito, Daniel Natera de, Osorio, A Nascimento, Maggi, Lorenzo, Bönnemann, C, McAnally, Meghan , Schara-Schmidt, Ulrike, Marina, Adela Della , Kostera-Pruszczyk, Anna, Milone, Margherita , Evoli, Amelia , Jungbluth, Heinz, Lochmüller, H., Beeson, D. J., Reddel, Stephen SW, Palace, Jacqueline, Palace, Jacqueline , Jungbluth, Heinz , Beeson, David , Palace, Jacqueline , Munot, Pinki , Benito, Daniel Natera‐de , Maggi, Lorenzo , Bönnemann, Carsten G. , Schara, Ulrike , Kostera‐Pruszczyk, Anna , Reddel, Stephen

Mayo Clinic

Brain | February 2, 2026 | Volume: 149 | Issue: 6 | Pages: 1816-1818

10.1093/brain/awag035 | PMID 41630153 Get It

Ramdas et al. propose renaming ‘congenital myasthenic syndrome’ as ‘genetic myasthenic syndrome’. They argue that ‘congenital’ misleadingly implies neonatal onset, which may contribute to delayed diagnosis and management, and that revised nomenclature could improve patient outcomes.
Clinical Considerations for Hormone Therapy in Idiopathic Primary Ovarian Insufficiency
Ferguson, Dewonna , Shihab, Sara, David, Paru, Vegunta, Suneela

Mayo Clinic

Journal of Women's Health | February 2, 2026 | Volume: 35 | Issue: 6 | Pages: 608-610

10.1177/15409996261422118 | PMID 41626774 Get It

Optimizing tuberculosis post-exposure follow-up among healthcare personnel using a risk-based approach
Samreen, Ayesha, Swift, Melanie D. , Breeher, Laura E. , Apenhorst, Debra, Rasmusson, Jenna, Loeffler, April, Anderson, J. Simon, Shah, Aditya , Samreen, Ayesha , Samreen, Ayesha , Apenhorst, Debra K, Rasmusson, Jenna M., Loeffler, April R, Anderson, Jennifer A, Shah, Aditya S , Swift, Melanie D , Breeher, Laura , Anderson, Jennifer A.

Mayo Clinic

Infection Control & Hospital Epidemiology | February 2, 2026 | Volume: 47 | Issue: 5 | Pages: 530-532

10.1017/ice.2026.10403 | PMID 41623146 Get It

Abstract Healthcare personnel (HCP) are at risk for occupational exposure to tuberculosis. Current guidelines for managing exposed HCP are broad and resource intensive. Based on review of our internal data, we propose a risk-based stratification approach to streamline exposure follow-up testing and optimize resource utilization.
Severity of physical, emotional, and cognitive symptoms is associated with future persistence of acute post-traumatic headache attributed to mild traumatic brain injury
Mao, Lingchao , Li, Jing, Dumkrieger, Gina , Smith, Dani C., Leonard, Michael, Chirravuri, Richa, Wu, Teresa, Ross, Katherine, Starling, Amaal, Schwedt, Todd J. , Chong, Catherine D., Mao, Lingchao , Chong, Catherine D , Schwedt, Todd J , Dumkrieger, Gina , Li, Jing, Chirravuri, Richa, Ross, Katherine , Chong, Catherine D.

Mayo Clinic

Cephalalgia | February 2, 2026 | Volume: 46 | Issue: 2 | Pages: No page available

10.1177/03331024251414856 | PMID 41622920 Get It

Aim Post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI) frequently co-occurs with other physical, cognitive, and emotional symptoms. This study assessed associations between PTH improvement and these symptoms in individuals with acute headaches (APTH) and compared symptoms between those who had recently developed persistent PTH (PPTH) to those who had long-standing PPTH. Methods This study included 105 individuals with APTH (mean age = 43.4, SD = 15.8; 70 females, 35 males) and 46 individuals with PPTH (mean age = 38.2, SD = 10.9; 16 females, 30 males) with an average duration of 11.3 years from two prospective longitudinal studies. For those who had APTH, PTH improvement was assessed at three months post-enrollment using an electronic headache diary. Participants completed questionnaires evaluating physical (including headache symptoms, photosensitivity, hyperacusis, insomnia, autonomic symptoms, and disability), emotional (including depression, anxiety, pain catastrophizing, and post-traumatic stress disorder screening), and cognitive symptoms (including memory and attention). The APTH cohort completed questionnaires at baseline, follow-up #1 (three to four months from baseline), and follow-up #2 (six to seven months from baseline). Mixed Effects Models were used to analyze the temporal trend of symptoms among the APTH improved and non-improved groups. Results Among the 105 individuals with APTH, 60 experienced PTH improvement and 45 did not. At baseline, compared to those who had PTH improvement, those who did not have PTH improvement had higher SCAT total scores and physical subscores, greater levels of hyperacusis, pain catastrophizing, anxiety and depression. At follow-up #1 (three to four months), these individuals continued to show more pronounced physical and emotional symptoms and worse cognitive function and insomnia. Most of these group differences persisted at follow-up #2 (six to seven months). Most symptoms showed progressive improvement over three months for individuals who had PTH improvement but not for those without PTH improvement. Furthermore, individuals with long-standing PPTH showed more severe insomnia, pain catastrophizing, and PTSD compared to those who had recently developed PPTH. Conclusion Individuals with APTH who did not experience PTH improvement at three months had more severe physical, cognitive, and emotional symptoms at baseline compared to those who had PTH improvement. While most symptoms normalized in individuals with PTH improvement, symptoms overall persisted at three and at six months for those with PTH persistence. Individuals who had long-standing PPTH had more severe insomnia and more negative cognitive/emotional responses to pain compared to those who had recently developed PPTH.
Capturing the inflammatory landscape within kidney compartments of human diabetic kidney disease: a digital spatial profiling study
Elhusseiny, Khaled M., Deceus, Farha G., Cornell, Lynn D., Bian, Xiaohui, Ma, Yaohua , Kachergus, Jennifer M., Thompson, E. Aubrey, El-Husseiny, Khaled M., Deceus, Farha G. , Cornell, Lynn D. , Bian, Xiaohui , Kachergus, Jennifer M., Hickson, LaTonya J.

Mayo Clinic

Frontiers in Endocrinology | February 2, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fendo.2026.1744430 | PMID 41704489 Get It

Objective To quantitatively examine immune cell markers and spatial distribution in human diabetic kidney disease (DKD) to enhance understanding of the inflammatory landscape contributing to injury. Maladaptive inflammation is an underrecognized contributor to DKD pathogenesis and progression and remains undertreated. Patients and methods NanoString GeoMx™ Digital Spatial Profiling technology targeted antibodies labeled with unique oligonucleotide barcode in kidney biopsy [DKD (n=5), tubulointerstitial nephritis (TIN; n=4), and normal (n=2)] with regions of interest selection of compartments (glomeruli, tubules, interstitium). Inflammation-related proteins were analyzed with differential expression through linear mixed modeling. Results Compared to normal tissue, inflammatory cell surface protein markers were increased in DKD tubules and interstitium. Markers of T cells (CD4, CD44), macrophages (CD68; proinflammatory), and antigen-presenting cells (APCs; CD40 and CD11c) were increased across all DKD compartments (vs. normal). Macrophage (CD163; prorepair) marker was increased in DKD tubules and interstitium (vs. normal). Fewer differences were observed in glomeruli for normal vs. DKD or TIN vs. DKD groups. CD66b+ (granulocytes) cell marker was higher in DKD (vs. TIN). As expected, TIN had higher levels of T cell and macrophage markers in tubules and interstitium (vs. DKD). Interestingly, CD34, a hematopoietic stem cell and endothelial cell marker, was lower in DKD tubules and interstitium (vs. normal) but higher in DKD (vs. TIN). Conclusion NanoString GeoMx DSP technology may fulfil a role in enhancing the understanding the inflammatory landscape engaged in DKD pathogenesis as well as measuring response to therapy. Moreover, additional investigations of CD34 progenitor cell depletion in DKD may be warranted.
Present Electrically Evoked Compound Action Potentials and Lack of Auditory Sensation Through a Cochlear Implant After Vestibular Schwannoma Resection
Kolberg, Courtney, Babajanian, Eric E. , DeJong, Melissa D., Deep, Nicholas L. , Dornhoffer, James R. , Neff, Brian A., Driscoll, Colin L.W., Carlson, Matthew L., Saoji, Aniket A. , Kolberg, Courtney, Driscoll, Colin L. W., Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | February 2, 2026 | Volume: 47 | Issue: 4 | Pages: e623-e626

10.1097/mao.0000000000004846 | PMID 41622559 Get It

Objective: Auditory nerve monitoring through electrically evoked compound action potentials (eCAP) can be used to assess cochlear neural integrity during vestibular schwannoma (VS) resection. Herein, we report on 5 cochlear implant (CI) patients who underwent VS resection with present eCAP responses both intraoperatively and postoperatively. Patients either did not perceive any sound through their CI or rapidly adapted to electrical stimulation, suggesting that the presence of eCAP does not guarantee auditory nerve function in patients with VS resection. Patients: Five patients who underwent simultaneous VS translabyrinthine resection and cochlear implantation. Interventions: Simultaneous cochlear implantation and translabyrinthine microsurgical VS resection. Main outcome measure: Electrically evoked compound action potential. Results: All patients had eCAP responses present during their VS resection and for at least 50 days post-surgery. Three of the 5 patients did not perceive any sound with their cochlear implant. This shows that the presence of an eCAP alone does not guarantee a functional auditory nerve or auditory perception. The other 2 patients could hear non-speech sounds, but these sounds quickly became inaudible, indicating that their auditory nerve lacked the ability to integrate the electrical stimulus over time. Conclusions: The presence of an eCAP response does not guarantee auditory sensation through a CI. Although eCAP measurements provide insight into the function of the distal end of the nerve, it does not ascertain integrity or function of the larger auditory nerve pathway. Therefore, eCAPs should not be used in isolation to monitor auditory nerve function during VS resection.
Efficacy and Safety of Apixaban in Cancer-Associated Thromboembolism: A Narrative Review
Aperna, Fnu, Kumar, Mahesh, Ahmad, Rimsha, Niaz, Mahnoor, Khan, Saifullah, Vakhshoori, Mehrbod, Arslan, Fatima Safi , Frishman, William H., Aronow, Wilbert S., Ahmad, Rimsha , Niaz, Mahnoor, Khan, Saifullah , Vakhshoori, Mehrbod , Frishman, William H. , Aronow, Wilbert S.

Mayo Clinic

Cardiology in Review | February 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001195 | PMID 41622537 Get It

Cancer-associated venous thromboembolism (CA-VTE) is a leading, severe, and potentially life-threatening complication in patients with malignancy. Low–molecular-weight heparin has historically been the standard of care; however, direct oral anticoagulants, particularly direct factor Xa inhibitors, have emerged as effective alternatives. These agents offer the convenience of oral administration, predictable pharmacokinetics, elimination of routine laboratory monitoring, and improved adherence. Despite the expanding role of direct oral anticoagulants in CA-VTE management, concerns regarding bleeding risk—particularly in patients with gastrointestinal and genitourinary malignancies—remain central to clinical decision-making. In this narrative review, we evaluate the efficacy, safety, and clinical applicability of apixaban for the treatment and prophylaxis of CA-VTE. Current evidence from randomized controlled trials, including CARAVAGGIO and AMPLIFY, demonstrates that apixaban has noninferior efficacy compared with low–molecular-weight heparin and conventional anticoagulation strategies, with comparable or lower rates of recurrent venous thromboembolism. In addition, apixaban appears to have a favorable safety profile, with no statistically significant increase in major bleeding in selected cancer populations, including those without active gastrointestinal lesions. Apixaban’s pharmacokinetic properties, including limited renal clearance and stable drug exposure, further enhance its clinical utility in oncologic populations. However, evidence supporting apixaban use across all cancer subtypes remains limited and heterogeneous, highlighting the need for additional comparative and real-world studies.
Inflammation and Immunogenetics in Cardiomyopathies: From Molecular Mechanisms to Therapeutic Perspectives
Peretto, Giovanni , Villatore, Andrea, Cooper, Leslie T., Villatore, Andrea , Villatore, Andrea , Cooper, Leslie T , Peretto, Giovanni , Cooper, Leslie T.

Mayo Clinic

Immunological Reviews | February 2, 2026 | Volume: 338 | Issue: 1 | Pages: No page available

10.1111/imr.70105 | PMID 41622435 Get It

ABSTRACT Genetic variants that impair cardiac function or predispose individuals to autoimmune diseases can influence both the risk and severity of inflammatory heart diseases, including lymphocytic myocarditis and cardiac sarcoidosis. We review recent clinical and experimental studies that describe the emerging interplay between genetic susceptibility and active myocardial inflammation. We summarize the current perspective on the mechanisms of inflammatory pathways and gene‐immune interactions, and explore the emerging therapeutic approaches aimed at targeting inflammation in genetic cardiomyopathies.
Fat-Soluble Vitamins: Deficiency and Excess
Tsichlis, Jason T. , Hauser, Brady, Rodriguez, Victoria A.

Mayo Clinic

Pediatrics in Review | February 1, 2026 | Volume: 47 | Issue: 2 | Pages: 67-77

10.1542/pir.2025-006770 | PMID 41620090 Get It

Influence of Social Media on Food Choices and Consumption Patterns of Undergraduates in a Nigerian University: A Cross-Sectional Study
Okoruwa, Juliet Obiageli , Ovedje, Tina E., Adeleke, F. N., Oladosu, G., Akinboboye, Praise O., Bolajoko, Opeyemi , Oladosu, Gbenga S. , Bolajoko, Opeyemi

Mayo Clinic

BioSocial Health journal | January 31, 2026 | Volume: 2 | Issue: 3 | Pages: 109-115

10.34172/bshj.83 Get It

Introduction: Social media plays a significant role in shaping the behaviors of undergraduates, including food choices. This study examined the influence of social media on food choices and consumption patterns among undergraduates at a Nigerian university. Methods: A descriptive cross-sectional study of 400 students was conducted using multistage sampling. Data were collected via a pre-tested, interviewer-administered questionnaire on sociodemographic, food consumption, social media use, and its perceived influence on food choices. Analyses were conducted in SPSS v29, reporting means, standard deviations, frequencies, and percentages. Binary logistic regression assessed associations between social media use and food consumption, with significance at P<0.05. Results: Respondents’ mean age was 21.17 ± 2.00 years, with 49.8% aged 15–20. WhatsApp (84.2%) and YouTube (80.7%) were the most used platforms. Over 60% reported that social media influenced their food choices. Confectioneries (70.5%), vegetables (62.5%), and oils (62.3%) were commonly consumed, while alcohol was least consumed (14.5%). Higher social media use was significantly associated with frequent meat and poultry consumption (OR=2.18, P=0.018) and lower odds of oil consumption (OR=0.42, P=0.002). Conclusion: The findings highlight the influence of social media on students’ diets, suggesting the need for nutrition professionals to promote healthier food choices through social platforms.